scholarly journals Multiple myeloma with G‐CSF production mimicking chronic neutrophilic leukemia

eJHaem ◽  
2021 ◽  
Author(s):  
Hiroshi Ureshino ◽  
Koichi Ohshima ◽  
Masaharu Miyahara
2007 ◽  
Vol 42 (2) ◽  
pp. 151
Author(s):  
Sollip Kim ◽  
Chan-Jeong Park ◽  
Kyoo Hyung Lee ◽  
Seongsoo Jang ◽  
Hyun Sook Chi ◽  
...  

Cancer ◽  
1990 ◽  
Vol 66 (1) ◽  
pp. 162-166 ◽  
Author(s):  
Graham R. Standen ◽  
Bharat Jasani ◽  
Michael Wagstaff ◽  
Charles A. J. Wardrop

1984 ◽  
Vol 70 (1) ◽  
pp. 105-107 ◽  
Author(s):  
Fabrizio Franchi ◽  
Patrizia Seminara ◽  
Giuseppe Giunchi

A case of chronic neutrophilic leukemia associated with multiple myeloma is described. The patient appears to be the longest surviving case reported in the literature. Since myeloma developed several years after leukemia, the possible precancerous role of myeloproliferative syndromes is proposed.


2002 ◽  
Vol 43 (3) ◽  
pp. 649-651 ◽  
Author(s):  
GünÇağ DinÇol ◽  
Meliha NalÇacI ◽  
Öner Doğan ◽  
Melih Aktan ◽  
Reyhan KüÇükkaya ◽  
...  

2015 ◽  
Vol 9 (5) ◽  
pp. 2208-2210 ◽  
Author(s):  
JINNING SHI ◽  
YING NI ◽  
JIANYONG LI ◽  
HAIRONG QIU ◽  
KOURONG MIAO

2020 ◽  
Author(s):  
Manxiong Cao ◽  
Zhanqin Huang ◽  
Huanbing Zhou ◽  
Dongqing Zhang

Abstract BackgroundLeukemoid reaction refers to reactive leukocytosis exceeding 50,000 cells/µl. Chronic neutrophilic leukemia is a rare clonal hematopoietic disorder characterized by sustained mature neutrophilia in the absence of monocytosis or basophilia. The differentiation between leukemoid reaction and chronic neutrophilic leukemia is problematic because both conditions share similar morphological features. Case presentationHere, we present an extremely rare case of a 62-year-old male patient who was initially diagnosed with chronic neutrophilic leukemia at another hospital. When the patient came to our hospital, no mutations in the CSF3R, SETBP1, ASXL1, TET2, SRSF2, SF3B1, ZRSR2 and U2AF1F genes were found by whole-exon sequencing. Further examination revealed the presence of immunoglobulin G kappa myeloma. Meanwhile, colonoscopy showed a mass in the colon, and biopsy confirmed the presence of colon adenocarcinoma. Therefore, we suggest that the increased white blood cell count in the patient was merely a neutrophilic leukemoid reaction caused by synchronous multiple myeloma and colon carcinoma.ConclusionThis is the first report of a case of coexisting multiple myeloma and colon carcinoma presenting with a neutrophilic leukemoid reaction. This case was presented to illustrate that the diagnosis of chronic neutrophilic leukemia must meet the strict WHO diagnostic criteria, especially if there is an underlying plasma cell disorder, and myeloid clonality must be demonstrated to make a distinction between chronic neutrophilic leukemia and leukemoid reaction. Meanwhile, this case provides us with a reference that further examination, especially pathological examination, should be performed on a patient diagnosed with multiple myeloma, who has extramedullary lesions, because other primary tumors may be also presenting the very similar symptoms. Pathological examination is helpful to differentiate the primary tumor from extramedullary invasion of multiple myeloma.


2014 ◽  
Vol 2014 ◽  
pp. 1-3
Author(s):  
Evelyn Taiwo ◽  
Huiying Wang ◽  
Robert Lewis

A 63-year-old female was incidentally found to have leukocytosis and referred to the hematology service for evaluation. Complete blood count (CBC) revealed neutrophilia with band predominance and mild thrombocytopenia. Peripheral blood flow cytometry was unremarkable without any evidence of lymphoproliferative disorder or myeloblasts. Bone marrow aspiration and biopsy revealed a markedly hypercellular marrow with myeloid lineage predominance and approximately 10% plasma cells. The monoclonal gammopathy was determined as lambda light chain with a kappa/lambda ratio of 0.06. Cytogenetics revealed normal karyotype, JAK2 kinase was negative, and rearrangement of BCR-ABL1, PDGFRA, PDGFRB, and FGFR1 was negative. The patient was diagnosed with chronic neutrophilic leukemia (CNL) associated with light chain multiple myeloma, complicated by a subdural hemorrhage. She was treated with hydroxyurea and bortezomib/dexamethasone and had complete response with normalization of CBC and kappa/lambda ratio. To the best of our knowledge, we report the first case of chronic neutrophilic leukemia and multiple myeloma treated with bortezomib/dexamethasone.


2005 ◽  
Vol 41 ◽  
pp. 205-218
Author(s):  
Constantine S. Mitsiades ◽  
Nicholas Mitsiades ◽  
Teru Hideshima ◽  
Paul G. Richardson ◽  
Kenneth C. Anderson

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies, because of the pleiotropic cell-cycle regulators and modulators of apoptosis that are controlled by proteasome function. In this chapter, we review the current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the U.S. Food and Drug Administration for the treatment of advanced multiple myeloma. Particular emphasis is placed on the pre-clinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and a appraisal of possible uses in other haematological malignancies, such non-Hodgkin's lymphomas.


2000 ◽  
Vol 111 (4) ◽  
pp. 1118-1121 ◽  
Author(s):  
A. Bellahcene ◽  
I. Van Riet ◽  
C. de Greef ◽  
N. Antoine ◽  
M. F. Young ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document